论文部分内容阅读
目的:观察吉西他滨联合洛铂在复发转移性鼻咽癌治疗中的疗效。方法:选取我院2015年4月至2016年4月收治的复发转移性鼻咽癌患者的50例,随机分为GL组和GP组,均为25例。GL组采用吉西他滨联合洛铂,GP组采用吉西他滨联合顺铂,比较两组治疗效果及不良反应。结果:经治疗后,GL组有效率为60%(15/25),GP组为52%(13/25),两组比较无显著性差异(P>0.05);GL不良反应发生率较低。结论:吉西他滨联合洛铂治疗复发转移性鼻咽癌与吉西他滨联合顺铂治疗的近期疗效基本相当,且毒副反应较之更轻,患者易耐受,是较为理想的化疗方案,值得临床推广使用。
Objective: To observe the effect of gemcitabine combined with lobaplatin in the treatment of recurrent metastatic nasopharyngeal carcinoma. Methods: Fifty patients with recurrent metastatic NPC who were treated in our hospital from April 2015 to April 2016 were randomly divided into GL group and GP group, all of which were 25 cases. Gemcitabine combined with lobaplatin in GL group, gemcitabine combined with cisplatin in GP group, and the curative effect and adverse reactions in both groups were compared. Results: After treatment, the effective rate of GL group was 60% (15/25), GP group was 52% (13/25), there was no significant difference between the two groups (P> 0.05); the incidence of GL adverse reaction was lower . Conclusion: Gemcitabine combined with Losoplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma combined with gemcitabine and cisplatin has nearly equal curative effect in the short term, and the side effects are lighter and the patients are more tolerable, which is an ideal chemotherapy regimen and worthy of clinical application .